CD8A and breast cancer: Administration of low dose DC101, a VEGFR2 inhibitor, in combination with a mitomycin C vaccine leads to a higher infiltration of CD4+ and CD8+ cells and lower levels of MDSCs and Tregs, resulting in decreased hypoxia, breast cancer cell proliferation and increased survival [154].